🧠 FASTEST Trial @ ISC 2026 — A Precision Wake-Up Call in ICH Care
The results presented at ISC 2026 reinforce a hard truth in acute stroke:
⚠️ The right drug, given too late — or to the wrong patient — won’t change outcomes.
In the FASTEST trial: rFVIIa reduced hematoma growth
But did not improve overall functional outcomes (OR 1.09, 95% CI 0.79–1.51)
Where did benefit emerge? 👇
🎯 CTA spot sign patients — OR 1.86
⏱️ Treatment within 90 minutes — OR 1.82
The message isn’t that hemostatic therapy fails. It’s that patient selection + speed = impact.
Why This Matters Operationally
🚑 When treatment windows are measured in minutes — and benefit is concentrated in identifiable subgroups — clinical teams need support that is:
⚡ Fast
🎯 Precise
📊 Actionable
The Shift: From “Treatment for All” to “Treatment for the Right Patient”
🔬 The era of precision stroke intervention isn’t coming — it’s here. And precision therapy requires precision diagnostics.
At PurpleAI Inc., we are building AI systems designed for exactly this moment — where early detection, expansion risk stratification, and workflow-integrated decision support can unlock meaningful clinical benefit.
#StrokeCare #ISC2026 #FASTEST #BrainHemorrhageDetection #Neurology #MedicalAI #PrecisionMedicine #HematomaExpansion